P09 A Phase 2, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (V116) in adults ≥50 years

BACKGROUND: V116 is an investigational 21-valent PCV containing the following pneumococcal polysaccharides: 3, 6A, 7F, 8, 9N, 10A, 11A,12F, 15A, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B, and a de-O-acetylated 15B (deOAc15B). This phase 2 study evaluated the safety, tolerability, and immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Omole, Tosin, Cardona, Jose, Fraser, Neil J, Pagnussat, Sandra, Mularski, Richard, Andrews, Charles, Daboul, Nizar, Sapre, Aditi, Li, Jianing, Fernsler, Doreen, Xu, Weifeng, Gallagher, Nancy, Hall, Lori, Platt, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848835/
http://dx.doi.org/10.1093/jacamr/dlac133.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848835/
http://dx.doi.org/10.1093/jacamr/dlac133.013

Ejemplares similares